Literature DB >> 24743544

Genetic variants may play an important role in mRNA-miRNA interaction: evidence for haplotype-dependent downregulation of ABCC2 (MRP2) by miRNA-379.

Anneke N Werk1, Henrike Bruckmueller, Sierk Haenisch, Ingolf Cascorbi.   

Abstract

BACKGROUND: The functional influence of single-nucleotide polymorphisms (SNPs) of the ATP-binding cassette (ABC) transporter ABCC2 (MRP2) has been characterized in numerous studies. The aim of this study was to address the question of whether distinct ABCC2 haplotypes, which differ in their mRNA secondary structures, show an influence on the degree of mRNA and protein downregulation through miRNA interaction.
METHODS: A model using human peripheral blood monocytic cells (PBMCs) isolated from healthy Caucasian volunteers, with three defined ABCC2 haplotypes comprising the 5'-UTR SNP -24C>T, the 1249G>A SNP (V417I), and the silent 3972C>T SNP, was outlined. Cells were transiently transfected with miRNA-379, already known to target ABCC2 in HepG2 cells.
RESULTS: ABCC2 was downregulated through miR-379 in a haplotype-dependent manner: the wild-type CGC/CGC was modestly affected (mRNA: -12.7±4.2%, protein: -9.9±0.1%), whereas variant haplotypes were more strongly suppressed: CGT/CGT (mRNA: -36.7±2.4%, protein: -21.6±0.4%) and TGT/TGT (mRNA: -55.7±1.2%, protein: -46.3±4.0%). In addition, glutathione-methylfluorescein efflux was significantly reduced in miR-379-transfected peripheral blood monocytic cells corresponding to ABCC2 protein expression.
CONCLUSION: This observation may suggest a differential suppression of ABCC2 by miR-379 caused by haplotype-dependent differences in mRNA secondary structures, resulting in changes in mRNA target accessibility or mRNA stability.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24743544     DOI: 10.1097/FPC.0000000000000046

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  9 in total

Review 1.  MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Authors:  Ai-Ming Yu; Ye Tian; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek
Journal:  Drug Metab Dispos       Date:  2015-11-13       Impact factor: 3.922

2.  In Vitro Transport Activity and Trafficking of MRP2/ABCC2 Polymorphic Variants.

Authors:  Xia Wen; Melanie S Joy; Lauren M Aleksunes
Journal:  Pharm Res       Date:  2017-04-12       Impact factor: 4.200

3.  Identification of a potential functional single nucleotide polymorphism for fatness and growth traits in the 3'-untranslated region of the PCSK1 gene in chickens.

Authors:  K Zhang; B H Cheng; L L Yang; Z P Wang; H L Zhang; S S Xu; S Z Wang; Y X Wang; H Zhang; H Li
Journal:  J Anim Sci       Date:  2017-11       Impact factor: 3.159

4.  Association of MDR1 gene (C3435T) polymorphism and gene expression profiling in lung cancer patients treated with platinum-based chemotherapy.

Authors:  Syed Subhani; Kaiser Jamil; Sharanabasappa Somanath Nirni
Journal:  Mol Diagn Ther       Date:  2015-10       Impact factor: 4.074

5.  Expression levels of JNK associated with polymorphic lactotransferrin haplotypes in human nasopharyngeal carcinoma.

Authors:  Gengqiu Luo; Yanhong Zhou; Wei Yi; Hong Yi
Journal:  Oncol Lett       Date:  2016-06-15       Impact factor: 2.967

Review 6.  A review of gigaxonin mutations in giant axonal neuropathy (GAN) and cancer.

Authors:  James J Kang; Isabelle Y Liu; Marilene B Wang; Eri S Srivatsan
Journal:  Hum Genet       Date:  2016-03-29       Impact factor: 4.132

Review 7.  MiRNAs and miRNA Polymorphisms Modify Drug Response.

Authors:  Mu-Peng Li; Yao-Dong Hu; Xiao-Lei Hu; Yan-Jiao Zhang; Yong-Long Yang; Chun Jiang; Jie Tang; Xiao-Ping Chen
Journal:  Int J Environ Res Public Health       Date:  2016-11-08       Impact factor: 3.390

Review 8.  Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma.

Authors:  Marta Alonso-Peña; Anabel Sanchez-Martin; Paula Sanchon-Sanchez; Meraris Soto-Muñiz; Ricardo Espinosa-Escudero; Jose J G Marin
Journal:  Cancer Drug Resist       Date:  2019-09-19

Review 9.  Germline variants in cancer therapy.

Authors:  Meike Kaehler; Ingolf Cascorbi
Journal:  Cancer Drug Resist       Date:  2019-03-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.